Evogene Stock Current Liabilities
| EVGN Stock | ILA 518.20 18.10 3.62% |
Evogene fundamentals help investors to digest information that contributes to Evogene's financial success or failures. It also enables traders to predict the movement of Evogene Stock. The fundamental analysis module provides a way to measure Evogene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evogene stock.
Evogene |
Evogene Company Current Liabilities Analysis
Evogene's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Evogene Current Liabilities | 6 M |
Most of Evogene's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evogene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Evogene has a Current Liabilities of 6 M. This is 99.66% lower than that of the Biotechnology sector and 98.9% lower than that of the Health Care industry. The current liabilities for all Israel stocks is 99.92% higher than that of the company.
Evogene Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evogene's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evogene could also be used in its relative valuation, which is a method of valuing Evogene by comparing valuation metrics of similar companies.Evogene is currently under evaluation in current liabilities category among its peers.
Evogene Fundamentals
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (24.02) % | |||
| Current Valuation | 8.8 M | |||
| Shares Outstanding | 41.22 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 3.37 % | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 73.01 X | |||
| Revenue | 930 K | |||
| Gross Profit | 163 K | |||
| EBITDA | (26.78 M) | |||
| Net Income | (27.79 M) | |||
| Cash And Equivalents | 65.36 M | |||
| Cash Per Share | 1.61 X | |||
| Total Debt | 2.39 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 12.74 X | |||
| Book Value Per Share | 0.74 X | |||
| Cash Flow From Operations | (24.72 M) | |||
| Earnings Per Share | (0.72) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 133 | |||
| Beta | 0.9 | |||
| Market Capitalization | 121.59 M | |||
| Total Asset | 76.3 M | |||
| Retained Earnings | (90 M) | |||
| Working Capital | 89 M | |||
| Current Asset | 95 M | |||
| Current Liabilities | 6 M | |||
| Z Score | 29.8 | |||
| Net Asset | 76.3 M |
About Evogene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evogene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evogene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evogene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Information and Resources on Investing in Evogene Stock
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.